244 related articles for article (PubMed ID: 28193239)
1. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice.
Parris AB; Zhao Q; Howard EW; Zhao M; Ma Z; Yang X
J Exp Clin Cancer Res; 2017 Feb; 36(1):28. PubMed ID: 28193239
[TBL] [Abstract][Full Text] [Related]
2. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.
Ma Z; Parris AB; Xiao Z; Howard EW; Kosanke SD; Feng X; Yang X
J Exp Clin Cancer Res; 2017 Jan; 36(1):6. PubMed ID: 28061785
[TBL] [Abstract][Full Text] [Related]
3. FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice.
Zhao Q; Parris AB; Howard EW; Zhao M; Ma Z; Guo Z; Xing Y; Yang X
Sci Rep; 2017 Sep; 7(1):11306. PubMed ID: 28900173
[TBL] [Abstract][Full Text] [Related]
4. Caloric restriction inhibits mammary tumorigenesis in MMTV-ErbB2 transgenic mice through the suppression of ER and ErbB2 pathways and inhibition of epithelial cell stemness in premalignant mammary tissues.
Ma Z; Parris AB; Howard EW; Shi Y; Yang S; Jiang Y; Kong L; Yang X
Carcinogenesis; 2018 Oct; 39(10):1264-1273. PubMed ID: 30107476
[TBL] [Abstract][Full Text] [Related]
5. Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.
Zhu P; Davis M; Blackwelder AJ; Bachman N; Liu B; Edgerton S; Williams LL; Thor AD; Yang X
Cancer Prev Res (Phila); 2014 Feb; 7(2):199-210. PubMed ID: 24322659
[TBL] [Abstract][Full Text] [Related]
6. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
[TBL] [Abstract][Full Text] [Related]
7. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer.
Hallett RM; Kondratyev MK; Giacomelli AO; Nixon AM; Girgis-Gabardo A; Ilieva D; Hassell JA
PLoS One; 2012; 7(3):e33976. PubMed ID: 22470504
[TBL] [Abstract][Full Text] [Related]
8. Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer.
Mezil L; Berruyer-Pouyet C; Cabaud O; Josselin E; Combes S; Brunel JM; Viens P; Collette Y; Birnbaum D; Lopez M
PLoS One; 2012; 7(9):e43409. PubMed ID: 23028451
[TBL] [Abstract][Full Text] [Related]
9. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
[TBL] [Abstract][Full Text] [Related]
10. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD
Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice.
Gil EY; Jo UH; Lee HJ; Kang J; Seo JH; Lee ES; Kim YH; Kim I; Phan-Lai V; Disis ML; Park KH
Breast Cancer Res Treat; 2014 Aug; 147(1):69-80. PubMed ID: 25104444
[TBL] [Abstract][Full Text] [Related]
12. Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention.
Wang X; Yao J; Wang J; Zhang Q; Brady SW; Arun B; Seewaldt VL; Yu D
Cancer Prev Res (Phila); 2017 Nov; 10(11):641-650. PubMed ID: 28877935
[TBL] [Abstract][Full Text] [Related]
13. ErbB2 and p38γ MAPK mediate alcohol-induced increase in breast cancer stem cells and metastasis.
Xu M; Ren Z; Wang X; Comer A; Frank JA; Ke ZJ; Huang Y; Zhang Z; Shi X; Wang S; Luo J
Mol Cancer; 2016 Jul; 15(1):52. PubMed ID: 27416801
[TBL] [Abstract][Full Text] [Related]
14. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.
Maric G; Annis MG; MacDonald PA; Russo C; Perkins D; Siwak DR; Mills GB; Siegel PM
Oncogene; 2019 Jun; 38(26):5294-5307. PubMed ID: 30914799
[TBL] [Abstract][Full Text] [Related]
15. The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
Dragowska WH; Weppler SA; Qadir MA; Wong LY; Franssen Y; Baker JH; Kapanen AI; Kierkels GJ; Masin D; Minchinton AI; Gelmon KA; Bally MB
BMC Cancer; 2011 Oct; 11():420. PubMed ID: 21961653
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.
Zhu Y; Zhang X; Liu Y; Zhang S; Liu J; Ma Y; Zhang J
Tumour Biol; 2012 Oct; 33(5):1349-62. PubMed ID: 22492237
[TBL] [Abstract][Full Text] [Related]
17. FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.
Paul R; Luo M; Mo X; Lu J; Yeo SK; Guan JL
Breast Cancer Res; 2020 Jun; 22(1):59. PubMed ID: 32493400
[TBL] [Abstract][Full Text] [Related]
18. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
Lee H; Saini N; Howard EW; Parris AB; Ma Z; Zhao Q; Zhao M; Liu B; Edgerton SM; Thor AD; Yang X
Sci Rep; 2018 May; 8(1):6829. PubMed ID: 29717218
[TBL] [Abstract][Full Text] [Related]
19. Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.
Liu J; Chen X; Ward T; Mao Y; Bockhorn J; Liu X; Wang G; Pegram M; Shen K
Int J Biochem Cell Biol; 2016 Feb; 71():12-23. PubMed ID: 26643609
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]